Hospital-Acquired Infections: Diagnostic Markets and Testing Developments, Treatments, Key Competitors and Trends15 Aug 2011 • by Natalie Aster
New York – When a Hospital-acquired infection (HAI) is suspected, hospitals need results quickly, which is good news for innovative diagnostic test makers, notes healthcare market research firm Kalorama Information. In its recent report, Hospital-Acquired Infections: Diagnostic Markets and Testing Developments, Treatments, Key Competitors and Trends, Kalorama predicts the combined world market for testing and treatment products for HAI will reach $10.3 billion in 2015, up from $9 billion in 2010, with higher growth experienced in the testing segment.
Kalorama's report finds nosocomial infections are an inherent part of any healthcare system and have a 5% infection rate of the 40 million hospital visits a year, causing 100,000 deaths in the U.S. annually. In an effort to decrease the rate of fatality, hospitals are shifting focus towards rapid discovery and treatment of nosocomial infections, driving sales of testing products.
"The growth opportunities are in testing," said Bruce Carlson, publisher of Kalorama Information. "The treatment market is slowing down, with a little growth in the future, which will be dominated by established pharmaceutical companies."
Published: July 2011
Price: US$ 3,995.00
Specific nosocomial infections that are candidates for testing innovation, include Pneumonia, which comprises nearly 20% of all HAIs with 300,000 cases annually and has an associated mortality rate of 30-70%, as well as MRSA, which accounts for nearly 20,000 deaths a year. According to Kalorama, 20-30% of these infections are preventable through intensive hygiene and control programs and the remaining 70-80% through more involved measures, such as hospital architecture and air sanitation and the use of disposable equipment and supplies.
"Everyone is interested in faster tests and immediate results," added Carlson. "Although the rate of infection won't change, quicker turnover will improve patient outcome and drive down mortality rates."
Kalorama Information's report, Hospital-Acquired Infections: Diagnostic Markets and Testing Developments, Treatments, Key Competitors and Trends, reveals the world market for HAI diagnostic and treatment markets, providing segmented market data for molecular and conventional testing. It also covers the development of new testing systems and products and provides an analysis on growing drug resistance.
- Emerging Markets for In Vitro Diagnostics (IVD in Brazil, Russia, India, China and Other Nations);
- Minimally Invasive Surgical Devices, World Market;
- Women's Health Diagnostic Testing Markets;
- Clinical Nutrition Products, 4th Edition;
- Asian Vaccine Markets;
- Sample Preparation and Library Preparation for DNA Sequencers (Results of The Kalorama Survey of Labs);
- DNA Sequencing Market Trends (Kalorama Survey of Labs Using Next-Gen and Capillary Systems).
To order the report or ask for sample pages contact firstname.lastname@example.org